NO941347L - Fremgangsmåte for fremstilling av et humant monoklonalt antistoff - Google Patents

Fremgangsmåte for fremstilling av et humant monoklonalt antistoff

Info

Publication number
NO941347L
NO941347L NO941347A NO941347A NO941347L NO 941347 L NO941347 L NO 941347L NO 941347 A NO941347 A NO 941347A NO 941347 A NO941347 A NO 941347A NO 941347 L NO941347 L NO 941347L
Authority
NO
Norway
Prior art keywords
crl
antibodies
human monoclonal
cell lines
preparation
Prior art date
Application number
NO941347A
Other languages
English (en)
Other versions
NO941347D0 (no
Inventor
Howard V Raff
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from NO870476A external-priority patent/NO176924C/no
Publication of NO941347L publication Critical patent/NO941347L/no
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Priority to NO941347A priority Critical patent/NO941347D0/no
Publication of NO941347D0 publication Critical patent/NO941347D0/no

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cellelinjer er blitt fremstilt som utskiller humane, monoklonale antistoffer som er i stand til å bindes til molekyler av forskjellige bak- teriearter. Disse antistoffer er blitt funnet å være beskyttende mot letale utfordringer av forskjellige bakterieslekter. Farmasøytiske pre- parater inneholdende disse antistoffer, som kan være i kombinasjon med andre monoklonale antistoffer, blodplasma- fraksjoner og antimikrobielle midler, og den profylaktiske og terapeutiske bruk av slike preparater ved behand- ling av infeksjoner, er beskrevet. Før innlevering av foreliggende patentsøknad ble de her beskrevne, kontinuerlig transformerte, humane cellelinjer 9B10, 4F10, 4B9, 7D7 og 9C3, deponert ved American Type Culture Collection og gitt betegnelsene CRL 90O6, CRL 9007, CRL 9008, CRL 9009 og CRL 9239.
NO941347A 1986-02-07 1994-04-14 Fremgangsmåte for fremstilling av et humant monoklonalt antistoff NO941347D0 (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO941347A NO941347D0 (no) 1986-02-07 1994-04-14 Fremgangsmåte for fremstilling av et humant monoklonalt antistoff

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82800586A 1986-02-07 1986-02-07
US94449586A 1986-12-19 1986-12-19
NO870476A NO176924C (no) 1986-02-07 1987-02-06 Antistoffpreparat til ikke-terapeutisk anvendelse
NO941347A NO941347D0 (no) 1986-02-07 1994-04-14 Fremgangsmåte for fremstilling av et humant monoklonalt antistoff

Publications (2)

Publication Number Publication Date
NO941347L true NO941347L (no) 1987-08-10
NO941347D0 NO941347D0 (no) 1994-04-14

Family

ID=27484149

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941347A NO941347D0 (no) 1986-02-07 1994-04-14 Fremgangsmåte for fremstilling av et humant monoklonalt antistoff

Country Status (1)

Country Link
NO (1) NO941347D0 (no)

Also Published As

Publication number Publication date
NO941347D0 (no) 1994-04-14

Similar Documents

Publication Publication Date Title
SE8605295D0 (sv) Monoclonal antibodies cross-reactive and crossprotective against p. aeruginosa serotypes
SE8700467L (sv) Monoklonala humanantikroppberedningar som er korsprotektiva
DK0585943T3 (da) Opløselige ligander for CD40
PT751781E (pt) Utilizacao de anticorpos monoclonais ou ligandos oligomericos soluveis no fabrico de um medicamento para a prevencao ou tratamento de desordens neoplasicas
RU94028282A (ru) Биспецифическое антитело, способ его получения, моноклональные антитела, фармацевтический препарат, фармацевтические наборы, способ удаления опухолевых клеток, применение биспецифического фрагмента антитела
NO972451L (no) Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
CA2310888A1 (en) Monoclonal human natural antibodies
NO924088D0 (no) Antistoffer, fremgangsmaate for deres fremstilling og anvendelse derav
MD970199A (en) Induction of a cytotoxic T-lymphocytic answer The invention relates to the medicine, particularly to the immunology and can be used for treatment of bacterial and parasitic infections, tumors and other diseases. The summary of the invention consists in the induction of a cytotoxic T-lymphocytic answer to human and animals by means of a composition consisting of an antigene and an antigenic formulati
AU6649996A (en) Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
ATE257390T1 (de) Verwendung eines bpi proteinproduktes als antithrombotisches mittel
ATE395081T1 (de) Lo-cd2a antikörper und dessen verwendungen zur hemmung von t-zell aktivierung und wachstum
EP0313378A3 (en) Methods and compositions for transient elimination of humoral immune antibodies
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
NO973875D0 (no) Fremgangsmåte for simulering av en immunrespons
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
GEP20002257B (en) Method for Reducing Fibrin Accumulation Speed, Prophylactics of Thrombus Complications and Treatment of Blood Vessels Diseases, Medicinal Composition and Medicinal Species
AU3437497A (en) Igg immunoglobulins and f(ab')2 fragments thereof, specific for drugs and metabolites thereof, and their use for detoxification purposes
NO941347L (no) Fremgangsmåte for fremstilling av et humant monoklonalt antistoff
WO1996020950A3 (en) Compositions and methods for treating rheumatoid arthritis
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
Ray et al. Adsorption of Plasma from Tumor-Bearing Hosts over Protein A-Containing Nonviable Staphylococcus aureus Cowan I: Possible Mechanism of Antitumor Reactions
Lundgren Induction and suppression of the cytotoxic activity of human lymphocytes in vitro by heterologous anti-lymphocyte serum
WO1990013660A3 (en) Human monoclonal antibodies to sero-specific determinants of gram-negative bacteria